What is Noble Financial's Estimate for UNCY Q2 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Noble Financial issued their Q2 2025 earnings estimates for shares of Unicycive Therapeutics in a report released on Thursday, May 15th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.07) for the quarter. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.04 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09.

UNCY has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and issued a $7.50 price objective on shares of Unicycive Therapeutics in a research note on Friday, April 11th. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $6.00 price target on the stock.

Unicycive Therapeutics Stock Up 0.7%

Shares of NASDAQ UNCY traded up $0.00 during midday trading on Monday, hitting $0.55. The stock had a trading volume of 470,108 shares, compared to its average volume of 1,491,731. The company has a market capitalization of $66.73 million, a price-to-earnings ratio of -0.57 and a beta of 2.14. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.00. The company has a fifty day moving average price of $0.59 and a 200 day moving average price of $0.61.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp lifted its stake in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after purchasing an additional 34,183 shares in the last quarter. XTX Topco Ltd lifted its position in Unicycive Therapeutics by 142.2% during the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after acquiring an additional 100,679 shares in the last quarter. Geode Capital Management LLC lifted its position in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after acquiring an additional 122,089 shares in the last quarter. Acuta Capital Partners LLC lifted its position in Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after acquiring an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC lifted its position in shares of Unicycive Therapeutics by 14.0% during the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after purchasing an additional 1,400,000 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.